Login to Your Account

Second Genome rounds up $42.6M in series B financing

By Michael Fitzhugh
Staff Writer

Wednesday, April 20, 2016

Pharma's growing recognition of the strategic importance of the microbiome in drug discovery as well as its alignment with the company's approach to development paved a path for Second Genome Inc. to close a $42.6 million series B round co-led by Pfizer Venture Investments and Roche Venture Fund.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription